M&A / Deals Eli Lilly doubles down on in vivo with $7bn Kelonia buyout Pharmaceutical TechnologyLilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.M&A / DealsGene Therapy PlatformRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Technology Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company’s chance of success. M&A / DealsGene Therapy PlatformRead full story Post navigation Previous: Asahi Kasei acquires German company AicurisNext: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
